Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
11/04/2024 | 17:17 | PR Newswire (Canada) | L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - BHC | TSX:BHC | Bausch Health Companies Inc |
11/04/2024 | 17:17 | PR Newswire (Canada) | Canadian Investment Regulatory Organization Trade Resumption - BHC | TSX:BHC | Bausch Health Companies Inc |
11/04/2024 | 17:08 | PR Newswire (Canada) | Suspension de la négociation par l'Organisme canadien de réglementation des investissements - BHC | TSX:BHC | Bausch Health Companies Inc |
11/04/2024 | 17:03 | PR Newswire (Canada) | Canadian Investment Regulatory Organization Trading Halt - BHC | TSX:BHC | Bausch Health Companies Inc |
31/05/2023 | 14:00 | PR Newswire (US) | OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease | TSX:BHC | Bausch Health Companies Inc |
17/05/2023 | 19:34 | PR Newswire (Canada) | L'OCRCVM permet la reprise de la négociation - BHC | TSX:BHC | Bausch Health Companies Inc |
17/05/2023 | 19:33 | PR Newswire (Canada) | IIROC Trade Resumption - BHC | TSX:BHC | Bausch Health Companies Inc |
17/05/2023 | 19:18 | PR Newswire (Canada) | Suspension de la négociation par l'OCRCVM - BHC | TSX:BHC | Bausch Health Companies Inc |
17/05/2023 | 19:17 | PR Newswire (Canada) | IIROC Trading Halt - BHC | TSX:BHC | Bausch Health Companies Inc |
17/05/2023 | 18:43 | PR Newswire (Canada) | ttIIROC Trading Halt - BHC | TSX:BHC | Bausch Health Companies Inc |
03/05/2023 | 12:58 | PR Newswire (Canada) | RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada | TSX:BHC | Bausch Health Companies Inc |
03/05/2023 | 12:58 | PR Newswire (Canada) | RYALTRIS(MD), une nouvelle association sous ordonnance en pulvérisateur nasal pour la rhinite allergique saisonnière (RAS) d'intensité modérée à grave, est maintenant disponible partout au Canada | TSX:BHC | Bausch Health Companies Inc |
22/12/2022 | 12:59 | PR Newswire (Canada) | First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans | TSX:BHC | Bausch Health Companies Inc |
22/12/2022 | 12:59 | PR Newswire (Canada) | ARAZLOMC (lotion de tazarotène, 0,045 %), la première lotion à base de tazarotène indiquée pour le traitement de l'acné vulgaire, est maintenant offerte aux patients du Québec, de l'Ontario, de l'Alberta et de la Saskatchewan dans le cadre des régi | TSX:BHC | Bausch Health Companies Inc |
12/10/2022 | 14:00 | PR Newswire (Canada) | SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION | TSX:BHC | Bausch Health Companies Inc |
05/10/2022 | 14:00 | PR Newswire (US) | Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022 | TSX:BHC | Bausch Health Companies Inc |
03/10/2022 | 14:00 | PR Newswire (US) | SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY | TSX:BHC | Bausch Health Companies Inc |
28/09/2022 | 14:09 | PR Newswire (US) | Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations | TSX:BHC | Bausch Health Companies Inc |
23/09/2022 | 12:59 | PR Newswire (Canada) | Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada | TSX:BHC | Bausch Health Companies Inc |
23/09/2022 | 12:59 | PR Newswire (Canada) | Bausch Health et Glenmark annoncent l'approbation du RYALTRIS MD au Canada | TSX:BHC | Bausch Health Companies Inc |
14/09/2022 | 15:00 | PR Newswire (US) | Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations | TSX:BHC | Bausch Health Companies Inc |
09/09/2022 | 13:00 | PR Newswire (Canada) | Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin | TSX:BHC | Bausch Health Companies Inc |
08/09/2022 | 22:45 | PR Newswire (US) | Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations | TSX:BHC | Bausch Health Companies Inc |
03/09/2022 | 00:27 | PR Newswire (Canada) | S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSX et à l'indice S&P/TSX 60 | TSX:BHC | Bausch Health Companies Inc |
02/09/2022 | 23:15 | PR Newswire (Canada) | S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index | TSX:BHC | Bausch Health Companies Inc |
31/08/2022 | 05:28 | PR Newswire (US) | Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes | TSX:BHC | Bausch Health Companies Inc |
22/08/2022 | 13:00 | PR Newswire (US) | Bausch Health Continuing Process Toward Separating Bausch + Lomb | TSX:BHC | Bausch Health Companies Inc |
11/08/2022 | 00:00 | PR Newswire (Canada) | Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit | TSX:BHC | Bausch Health Companies Inc |
10/08/2022 | 13:00 | PR Newswire (US) | Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE) | TSX:BHC | Bausch Health Companies Inc |
09/08/2022 | 13:00 | PR Newswire (Canada) | BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS | TSX:BHC | Bausch Health Companies Inc |